Traws Pharma Secures $72.6 Million for Bird Flu Treatment Development
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has finalized agreements to raise up to $72.6 million to support the development of its promising bird flu treatment, Tivoxavir Marboxil. The …
Traws Pharma Secures $72.6 Million for Bird Flu Treatment Development Read More